REVOLUTION MEDICINES INC. - COMMON STOCK

Revolution Medicines Announces Publication on the Discovery of and Translational Research for RMC-6236, an Investigational RAS(ON) Multi-Selective Tri-Complex Inhibitor Designed to Block Full Spectrum of Oncogenic RAS(ON) Proteins

09 4 2024 15:34:07 提供 Nasdaq GlobeNewswire

Revolution Medicines Announces Publications on the Discovery and Preclinical Profile of Representative of a New Class of RAS(ON) Multi-Selective Inhibitors Designed to Block Full Spectrum of Oncogenic RAS(ON) Proteins

08 4 2024 11:36:55 提供 Nasdaq GlobeNewswire

Revolution Medicines to Participate in Upcoming Investor Conferences

04 4 2024 16:05:04 提供 Nasdaq GlobeNewswire

Revolution Medicines to Deliver Multiple Presentations at the Upcoming American Association for Cancer Research Annual Meeting 2024

28 3 2024 16:05:40 提供 Nasdaq GlobeNewswire

Revolution Medicines Reports Fourth Quarter and Full Year 2023 Financial Results and Update on Corporate Progress

26 2 2024 16:05:50 提供 Nasdaq GlobeNewswire

Revolution Medicines to Report Financial Results for Fourth Quarter and Full Year 2023 After Market Close on February 26, 2024

20 2 2024 16:05:47 提供 Nasdaq GlobeNewswire

Revolution Medicines to Participate in Upcoming Investor Conferences

01 2 2024 16:05:00 提供 Nasdaq GlobeNewswire

Revolution Medicines to Present at 42nd Annual J.P. Morgan Healthcare Conference

04 1 2024 07:00:08 提供 Nasdaq GlobeNewswire

Revolution Medicines Completes Acquisition of EQRx

09 11 2023 09:10:58 提供 Nasdaq GlobeNewswire

Revolution Medicines and EQRx Stockholders Approve EQRx Acquisition

08 11 2023 11:30:46 提供 Nasdaq GlobeNewswire

Revolution Medicines Reports Third Quarter 2023 Financial Results and Update on Corporate Progress

06 11 2023 16:05:18 提供 Nasdaq GlobeNewswire

Leading Independent Proxy Advisory Firms ISS and Glass Lewis Recommend Revolution Medicines Stockholders Vote “FOR” Proposed Acquisition of EQRx, Inc.

01 11 2023 07:00:00 提供 Nasdaq GlobeNewswire

Revolution Medicines to Report Financial Results for Third Quarter 2023 After Market Close on November 6, 2023

31 10 2023 16:15:00 提供 Nasdaq GlobeNewswire

Revolution Medicines Presents Promising Clinical Activity and Safety Data from Phase 1/1b Trial of RMC-6236

22 10 2023 02:30:28 提供 Nasdaq GlobeNewswire

Revolution Medicines Presents Encouraging Clinical Data for RMC-6236 and RMC-6291 at 2023 Triple Meeting

13 10 2023 11:50:29 提供 Nasdaq GlobeNewswire

Revolution Medicines to Present New Clinical Data at Major Oncology Conferences and Host Investor Webcast

04 10 2023 16:05:07 提供 Nasdaq GlobeNewswire

Revolution Medicines Doses First Patient in Phase 1/1b Clinical Trial of RMC-9805, an Oral, Covalent, Mutant-Selective KRASG12D(ON) Inhibitor

19 9 2023 07:00:38 提供 Nasdaq GlobeNewswire

Revolution Medicines Announces Publication Describing Molecular Basis of Tri-Complex Inhibitors Targeting Oncogenic RAS(ON) Proteins

17 8 2023 16:05:58 提供 Nasdaq GlobeNewswire

Revolution Medicines Reports Second Quarter 2023 Financial Results and Update on Corporate Progress

08 8 2023 16:05:04 提供 Nasdaq GlobeNewswire

Revolution Medicines to Report Financial Results for Second Quarter 2023 After Market Close on August 8, 2023

03 8 2023 16:05:54 提供 Nasdaq GlobeNewswire